GlassScriptPhysician profile
Matthew Mccurdy
NPI 1134625726
$4,077.18
in general payments reported to CMS, 2019-2025
42 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $764 · 2023: $355 · 2024: $1,262 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,006 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,006.03 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $771.79 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $312.93 | 2021-2025 | Lifevest |
| Amgen INC. | $309.89 | 2021-2024 | Repatha |
| Pfizer INC. | $307.10 | 2022-2025 | |
| Abbott Laboratories | $243.63 | 2025 | Amplatzer Amulet, Amplatzer Talisman |
| Chiesi USA, INC. | $200.25 | 2024-2025 | Kengreal, Cleviprex |
| Penumbra, INC. | $148.17 | 2025 | Indigo System |
| Sanofi-Aventis U.S. LLC | $136.05 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $134.05 | 2021-2025 | Farxiga, Brilinta, Wainua |
| Medtronic, INC. | $130.05 | 2025 | Symplicity G3, Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.23 | 2021-2022 | |
| Grifols USA, LLC | $116.85 | 2021-2024 | Prolastin-C Liquid |
| Philips North America LLC | $116.56 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Novartis Pharmaceuticals Corporation | $79.35 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $67.48 | 2024 | Arcalyst |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $65.88 | 2025 | |
| Merck Sharp & Dohme LLC | $64.75 | 2022-2025 | Verquvo, Keytruda, Capvaxive |
| Janssen Pharmaceuticals, INC | $61.16 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $58.49 | 2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $53.97 | 2021-2022 | |
| Terumo Medical Corporation | $53.00 | 2022 | |
| Vifor Pharma, INC. | $52.24 | 2024-2025 | Zemaira |
| La Jolla Pharmaceutical Company | $52.11 | 2024-2025 | Giapreza |
| Actelion Pharmaceuticals US, INC. | $44.69 | 2024 | Uptravi, Opsumit |
| Livanova USA, INC. | $36.08 | 2022-2023 | Lifesparc |
| Kiniksa Pharmaceuticals, LTD. | $33.37 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $32.60 | 2024 | Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $29.59 | 2025 | |
| Shockwave Medical, INC | $23.76 | 2025 | |
| Atricure, INC. | $21.89 | 2022 | |
| Ge Healthcare | $20.85 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Stryker Corporation | $20.10 | 2025 | Flowtriever |
| Thrombolex, INC. | $19.07 | 2025 | Bashir Endovascular Catheter |
| Zoll Circulation INC | $18.91 | 2025 | Downstream Cartridge, Therox Ds2 Console, Catheter |
| Novo Nordisk INC | $17.94 | 2024 | Ozempic, Rybelsus |
| Verona Pharma, INC. | $16.51 | 2025 | Ohtuvayre |
| Biogen, INC. | $13.70 | 2021 | |
| Ucb, INC. | $12.56 | 2021 | |
| Amryt Pharma Holdings LTD | $12.46 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.31 | 2021 | |
| Mallinckrodt Hospital Products INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mccurdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.